Celgene Corp. stuck the landing at this year’s American Society of Hematology conference. It presented positive Phase III data for a Revlimid/dexamethasone (Rev/dex) combination to treat newly diagnosed multiple myeloma patients with continuous therapy. Based on this and other data, it rolled out a grand vision of Revlimid (lenalidomide) as key to almost every emerging aspect of the MM market from pre-symptomatic MM to continuous treatment to maintenance usage.
The biotech hopes to use data from MM-020 and from another study, MM-015, to garner a frontline Revlimid approval in the U.S. and the European Union. It intends to submit...